Further research should explore the combined effects of CP-673451 with other tyrosine kinase inhibitors, such as EGFR, FGFR, and VEGFR inhibitors, or chemotherapeutic agents to enhance the effectiveness of CCA treatments. This evidence concerns the gene KDR and cholangiocarcinoma.